Severity
Moderate
FDA Drug recall · Reported March 27, 2024
Failed Impurities/Degradation Specifications: Out of specification for organic impurities
Eugia US LLC recalled Nicardipine Hydrochloride Injection (2.5mg/mL), US, 25mg per 10mL, 10mL Vial, Rx only, D… - a moderate-severity action.
Nicardipine Hydrochloride Injection (2.5mg/mL), US, 25mg per 10mL, 10mL Vial, Rx only, D… was recalled by Eugia US LLC in March 27, 2024. Reason: Failed Impurities/Degradation Specifications: Out of specification for organic impurities. Check the official notice for the remedy. Verify recall #D-0390-2024 with the FDA Drug before acting.
The recall
Eugia US LLC issued this moderate-severity FDA Drug recall-Failed Impurities/Degradation Specifications: Out of specification for organic impurities.
Sourced from official FDA Drug enforcement records. Verify recall #D-0390-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0390-2024) was formally reported on March 27, 2024, with the manufacturer initiating the action on February 20, 2024. It is classified under Moderate severity (Class II), with a current status of Ongoing. Eugia US LLC is listed as the recalling firm, operating out of East Windsor, NJ. Federal records list the affected scope as 335,940 vials.
The documented reason for this recall is: Failed Impurities/Degradation Specifications: Out of specification for organic impurities Distribution data in the federal record shows the product reached: Nationwide within the United States. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
335,940 vials
Related Recalls
6
5 from same agency
Nicardipine Hydrochloride Injection (2.5mg/mL), US, 25mg per 10mL, 10mL Vial, Rx only, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520 NDC 55150-183-10
Failed Impurities/Degradation Specifications: Out of specification for organic impurities
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0390-2024 |
| Date reported | March 27, 2024 |
| Date initiated | February 20, 2024 |
| Recalling firm | Eugia US LLC |
| Firm location | East Windsor, NJ |
| Affected scope | 335,940 vials |
| Distribution | Nationwide within the United States |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 27, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.